Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AZD9291 in NSCLC patients with T790M mutation and CNS metastases after EGFR TKI failure
KCT0003183Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), brain metastases and Carcinomatous Meningitis (CM), sponsored by AstraZeneca. Started May 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on KCT0003183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003183.